Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

STADA expands branded product portfolio with addition of food intolerances area

  • 26/08/2015
  • Press Release

Bad Vilbel, August 26, 2015 – In order to strengthen its branded product portfolio, STADA Arzneimittel AG has acquired a company, including the relevant sales structures, that is primarily focused on the development and marketing of prescription-free OTC products against enzymatic food intolerances (histamine, fructose and lactose intolerance). The main sales driver is DAOSiN®, the world's only dietary food with the enzyme diamine oxydase.

The total purchase price is Euro 17.2 million in cash. The sellers are a number of private owners, a sales company as well as an investment company. The company is SCIOTEC Diagnostics Technologies GmbH, which is located in the Austrian city of Tulln. 17 employees will be taken over as part of the acquisition.

Sales expectations for the products acquired within the scope of the transaction for 2015 are approximately Euro 5.8 million, whereby the current sales are, for the most part, generated in equal parts in Germany and Austria as well as about 20 percent internationally through distributors. The Group expects that the acquisition will contribute directly to STADA's profit.

"As a result of the acquisition, we are expanding our branded product activities into the area of food intolerances in order to position ourselves appropriately in this lucrative market with strong global growth", says Hartmut Retzlaff, Chairman of the Executive Board at STADA Arzneimittel AG about the most recent acquisition.

Dr. Matthias Wiedenfels, who is responsible for Business Development & Central Services in the STADA Executive Board, adds: "We thus again show that we are making good progress toward continuously strengthening ourselves with smaller acquisitions in the area of margin attractive, prescription-free branded products".

 

Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]
 
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]